Clinical trial

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

NCT03751436

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-08-02

PhasePHASE1

Study timeline

Study start (actual)2019-08-02Date precision: day

Registry last updated2023-10-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Castration Levels of Testosteroneunresolved

Castration-Resistant Prostate Carcinomaunresolved

Metastatic Prostate Carcinomaunresolved

Metastatic Prostate Carcinoma in the Soft Tissueunresolved

Prostate Carcinoma Metastatic in the Boneunresolved

PSA Progressionunresolved

Stage IV Prostate Cancer AJCC v8unresolved

Stage IVA Prostate Cancer AJCC v8unresolved

Stage IVB Prostate Cancer AJCC v8unresolved

Interventions

EnzalutamideDRUG · verified · RxNorm: enzalutamide

VenetoclaxDRUG · verified · RxNorm: venetoclax

Sponsors & collaborators

Roswell Park Cancer Institutelead sponsor

AbbViecollaborator

Mapped research locations

BuffaloNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03751436 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.